Precision Medicine - Cancer Currents Blog
- PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations
Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.
- Studies Identify Potential Treatment Strategies for Pediatric DIPG Brain Tumors
Two studies have identified proteins that drive growth of diffuse intrinsic pontine glioma (DIPG) tumor cells. Blocking these targets with investigational drugs slowed tumor growth in animal models.
- Genome Study Points to New Subtypes of Esophageal Cancer
A new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
- New Targeted Therapies Show Promise for Treating Advanced GIST
Two new targeted therapies have shown promise in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to standard therapies.
- Single Tumor Cells Reveal Clues to Biology of Multiple Myeloma
A study suggests that individual tumor cells circulating in the blood of patients with multiple myeloma may be a new source of information about the genetic changes driving the disease.
- Scientists Identify Potential Marker of Resistance to PARP Inhibitors
Findings from a new study from NCI researchers could help predict whether a tumor will respond to a new class of promising cancer drugs, and identifies a potential way to overcome that resistance.
- Studies Highlight Potential of Targeting HIF-2 in Kidney Cancer
Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.
- Chromosomal Instability Score May Predict Response to Cancer Treatment
A new study suggests that a chromosomal instability score may help guide treatment choices for patients with cancer.
- Tumor DNA in Blood May Signal Response to T-Cell Transfer Immunotherapy
A study suggests that doctors could use circulating tumor DNA to quickly identify patients who are responding to T-cell transfer immunotherapy.
- Early-Stage Cancer Trials Support Promise of Precision Medicine, Immunotherapy
Encouraging findings from several early-stage clinical trials featured at the 2016 American Society of Clinical Oncology annual meeting support the promise of precision medicine and immunotherapy.
- Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack
The CFH antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side effects.
- How Genomics Is Shaping Precision Medicine in Oncology
In laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.
- For Some Children with Cancer, Genomic Information May Help Guide Treatment Decisions
Genomic methods, such as DNA sequencing, may help doctors manage the treatment of children and young adults with cancer.
- Test May Identify Poor Prognosis for Some Patients with Lung Cancer
A panel of three genetic markers may help to identify patients with early-stage lung cancer who have a very strong likelihood of their disease returning after surgery.
- Using Gene Expression to Diagnose Lung Cancer More Accurately
A pattern of gene expression in the cells of the upper airways of patients with suspected lung cancer can help to diagnose lung cancer more accurately than bronchoscopy alone.
- Collateral Damage: Missing Tumor Suppressor Gene Creates Opening for Cancer Treatment
Tumor cells that are missing one copy of the tumor suppressor gene TP53 often harbor another genetic alteration that may make them susceptible to a targeted attack, according to a new study.
- Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker
Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab (Keytruda®).
- The Exceptional Responders Initiative: Welcoming More Cases
The initiative is studying tissue, clinical, and genomic data from patients with cancer who have had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.
- Who Will Respond to PD-1 Inhibition? Study Provides Clues
A new study shows that specific DNA changes in a tumor may help determine which patients are most likely to respond to treatment with PD-1 inhibitors
- Genetic Studies Yield Clues to Treatment-Related Side Effects in Children with Cancer
Researchers have identified genetic variations in children with brain cancer that increased their risk of rapid hearing loss after treatment.
- Genome Study Yields Clues to Head and Neck Cancers
Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease, including in patients whose cancer is associated with the human papillomavirus (HPV).
- Precision Medicine Initiative® and Cancer Research
Under the Precision Medicine Initiative, NCI is working to accelerate the pace of research that will help identify which treatments work best for which patients.
- Which Patients Will Benefit from Immunotherapy for Cancer? Some Hints Emerge
Researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. The results could be the basis for a test that identifies likely responders to this treatment as well as for developing new treatments.
- Method for Identifying Combination Therapies to Combat Treatment Resistance Shows Promise
Researchers from the Massachusetts General Hospital Cancer Center in Boston have reported on a method for studying treatment resistance that may identify combinations of targeted therapies that can help to combat resistance in some patients.